CEFTAZIDIME FOR INJECTION, BP POWDER FOR SOLUTION

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

CEFTAZIDIME (CEFTAZIDIME PENTAHYDRATE)

Verfügbar ab:

STERIMAX INC

ATC-Code:

J01DD02

INN (Internationale Bezeichnung):

CEFTAZIDIME

Dosierung:

3G

Darreichungsform:

POWDER FOR SOLUTION

Zusammensetzung:

CEFTAZIDIME (CEFTAZIDIME PENTAHYDRATE) 3G

Verabreichungsweg:

INTRAVENOUS

Einheiten im Paket:

10X3G

Verschreibungstyp:

Prescription

Therapiebereich:

THIRD GENERATION CEPHALOSPORINS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0116900010; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2015-04-02

Fachinformation

PRODUCT MONOGRAPH
PR
CEFTAZIDIME FOR INJECTION BP
(as ceftazidime pentahydrate)
1 G/VIAL, 2 G/VIAL, 3 G/VIAL, 6 G/VIAL
Sterile Powder for Solution
ANTIBIOTIC
SteriMax Inc.
Date of Revision: February 9, 2018
2770 Portland Drive
Oakville, ON L6H 6R4
Control No.: 212129
_Ceftazidime for Injection BP _
_ _
_Page 2 of 51 _
_ _
PRODUCT MONOGRAPH
PR
CEFTAZIDIME FOR INJECTION BP
(as ceftazidime pentahydrate)
1 G/VIAL, 2 G/VIAL, 3 G/VIAL, 6 G/VIAL
Sterile Powder for Solution
ANTIBIOTIC
CLINICAL PHARMACOLOGY
_In vitro _ studies indicate that the bactericidal action of
ceftazidime, a semisynthetic cephalosporin
antibiotic, results from inhibition of bacterial cell wall synthesis.
Ceftazidime has a high affinity for the Penicillin-Binding Protein-3
(PBP-3) and moderate affinity for the
PBP-1a of certain Gram negative organisms such as _Escherichia _coli
and _Pseudomonas aeruginosa_. The
affinity for PBP-1b is much less than that for either PBP-3 or PBP-1a.
PBP-3 is involved in the process of
cross-wall formation (septation). Binding to this protein results in
formation of filaments and eventual
death of the bacterium. PBP-1a and PBP-1b are involved in longitudinal
wall synthesis (elongation) prior
to septation. Binding to these proteins results in spheroplast
formation followed by rapid lysis.
Ceftazidime has high affinity for PBP-1 and PBP-2 of _ Staphylococcus
aureus_. However, the drug's
affinity for PBP-3 is very much less in this organism.
INDICATIONS AND CLINICAL USE
Ceftazidime for Injection BP may be indicated for the treatment of
patients with infections caused by
susceptible strains of the designated organisms in the following
diseases:
LOWER RESPIRATORY TRACT INFECTIONS
Pneumonia caused by _ Pseudomonas aeruginosa_; _ Haemophilus
influenzae _including ampicillin-resistant
strains; _ Klebsiella _ species; _ Enterobacter _ species; _ Proteus
mirabilis;_ _ Escherichia coli, Serratia _ species,
_Streptococcus pneumoniae_, and _Staphylococcus_ _aureus_ (methicillin
susceptible) strains.
_Ceftazidime for Injection BP _